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Dietary Energy Availability  

Life Style Factors and Weight 
Mozaffarian et al., NEJM 2011 
Spot the Difference 
 Liposuction 
 28%-44% of abd fat 
 18% of total fat 
 No change in insulin 
sensitivity 
 muscle 
  liver 
 adipose tissue 
 No change 
 adiponectin, TNF alpha, 
IL 6 
 risk factors for CV 
disease 
Klein et al., NEJM 2004 
Fat Matters 
 40 subjects  
 BMI: 34.5-37.6 
 Body fat: 39-42% body wt 
 Group 1:  matched visceral fat 
vol 
 Normal intrahepatic fat 
 High intrahepatic fat  
 Group  2: matched intra-
hepatic fat  
Fabbrini et al Proc Natl Acad Sci 2009; Gastroenterology 2011 
3.6% vs 25.3% 
IHTG: 13.2% 
‘Fat body’ and Liver 
Hotamisligil Nature 2006 
Which came first? 
 38 yr male, BMI 36 
 Scrotal swelling- cellulitis 
 Venous blood glucose 33.3 
 Wt loss 6 mo; polydipsia 3 mo 
 Alcohol 20 unit 
 Maternal aunt with T2DM 
 PH 7.383; bicarb 20 
 urine 3+ ketones;  
 HbA1C 13.8% 
 Chol 7.6; Triglyceride 20.3 
 GGT 69 
 Started on Insulin and statin 
…..2009 
Progress 2010-12 
 ALT: 91 
GGT: 130 
Ferritin: 452 
HbA1C: 6.6-10-12%   
Update 
C peptide: 2473 
pmol/L 










Chronology of Metabolic syndrome 
 Adult treatment panel III criteria 
Suzuki et al., Hepatology 2005; Sattar et al., Diabetes 2005, 2007; 
Shibata et al., Diabetes care 2007, Lawlor et al., Am J Epidemiol 2005; 
Ghouri et al., Hepatology 2010 
NAFLD is pre-Diabetes 
Shibata M et al. Diabetes Care 2007.  Fraser et al. Diabetes Care 2009 . Musso G et al. Ann Med. 2011 
Twin cycle hypothesis 
Taylor R. Diabetologia 2008;51:1781–1789. 
Roots above, branches below 
Risk = Disease 
 BARD score 
 BMI 28 =1 
 AST/ALT ratio 0.8=2 
 DM=1 
 BARD score 2-4 = advanced fibrosis (OR: 17 [9-32]) 




























Good Fat, Bad Fat 
 Db/Db mice fed MCD diet 
 Diacyl glyceral acyl transferase 2 antisense oligonucleotide 
treatment 
Yamaguchi et al. Hepatology 2007 
Fat and insulin signalling 
Samuel VT et al. Cell 2012, Birkenfield AL et al. Hepatology 2014 
Lipogenesis or lipolysis 
Romeo et al. Nat Genet 2008 
Farrell. Hepatology 2010 
Coffee: magic  
Saab et al., Liv International 2013 
Smith et al., Diabetes Care 2006 
Coffee 
effect 
Greesner. Gastroenterology 2010 
Glitazones 
 7 RCT (n=489) 
 4 placebo controlled 
(n=355) 
 Improvement 
 Fibrosis: RR 1.38 
 Steatosis: RR 2.03  
 Inflammation: RR 1.7 
 Ballooning: 1.62 
 
Mahady et al. J Hepatology 20 11 
Secondary outcomes 
Sanyal et al., N Engl J Med 2010 
Aithal et al., Gastroenterology 2008 
Placebo Pioglitazone P value 
Weight (kg) - 0.55 + 2.77 0.02 
Glucose (mmol/ + 0.4 - 0.1 0.02 
HbA1C (%) + 0.16 - 0.18 0.01 
C peptide (pmol/l) + 42.0 78.2 0.02 
Dyslipidemia +3.4% -14.8% 0.05 
Pioglitazone: all outcomes 
 19 trials 
 16390 patients 
 4 mo- 3.5 years 
 Individual components all 
reduced 
 HR: 0.8- 0.92 
 Heart failure 2.3% vs 
1.8% 
Lincoff  et al. JAMA 2007 
Enterohepatic action of Farconoid Xenosensing Receptor (FXR) 
 Schaap, FG et al. Nat. Rev. Gastroenterol. Hepatol. 2014;11, 55–67. 
Obeticholic acid 
 First in class selective FXR agonist 
 100 fold activity compared to chenodeoxycholic acid 
 FGF19 in Ob/Ob mice 
 Reduced weight, adiposity, liver fat 
 Improved insulin sensitivity 
 Favourable lipid profile 
 FGF19 in FXR-deficient mice 
 Decreased intrahepatic triglyceride 
 FFA and ALT 
 FGF19 in insulin deficient animals 
 Restores glycogen loss from lack of insulin action 
 Obeticholic acid is anti-inflammatory and antifibrotic properties 
 
Primary end point  
Group Low dose insulin 
(mean % change in 
glucose infusion rate) 
P value High dose insulin 
(mean % change in 
glucose infusion rate) 
 
P value 
Placebo (n=17) -5.5% -5.4% 
OCA 25 mg 
(n=15) 
28.0% 0.019 18.3% 0.036 
OCA 50 mg 
(n=12) 
20.1% 0.06 10.8% 0.076 
OCA both doses 
(n=27) 
24.5% 0.01 15.0% 0.025 
Fall in ALT, GGT and ALP (not AST) 
Fall in ELF score 
Fall  HA, P3NP and TIMP 1 





NAFLD and Outcome 
Adams et al., Gastroenterology 2006 
Matteoni et al Gastroenterology 1999 
Fat Non-specific inflmn. Ballooning Fibrosis 
Cirrhosis 4% 0 21% 26% 
Liver death 2% 0 5% 13% 
Cirrhosis 4% vs. 22% (p=0.001) 
Liver related death 2% vs. 10% (p=0.08) 
Outcome beyond the liver 
Musso. Ann. Med. 2010 
Ghouri. Hepatology 2010 
Cardiovascular events 
Musso et al. Ann. Med. 2010 
Inflamed liver and heart 
 52 NAFLD; 28 controls 
 Flow mediated vasodialtion 
 GTN induced 
 Adjusted for age, gender, BMI, IR 
 NAFLD < Normal  
 NASH < steatosis 
 10 yr probability of CV events 
 NASH > NAFLD > Normal 
Villanova Hepatology 2005 
Beyond glucose 
 11,140 type 2 DM x 5 yrs 
 No effect on CV events, any death 
 Reduced nephropathy   
 10,251 type 2 DM x 3 yrs 
 No reduction in vascular events  
 Increased mortality- study discontinued 
 1791 type 2 DM x 6 yrs 
 No effect on CV events, death or microvascular complications 
 UKPDS: 5,102 patients with type 2DM x 10 years 
 No significant reduction in fatal, non-fatal MI or sudden death 
ADVANCE Col. Group. NEJM 2008; ACCORD Study Group NEJM 2008; 
Duckworth. NEJM 2009; UKPDS. Lancet 1998 
Heart of the Matter 
 3246 British women 
 60-79 yr 
 None with DM, coronary disease and stroke at base line 
 Fasting insulin had a linear relationship with vascular events 
 Fasting glucose, HbA1C had no effect 
Lawlor. PLoS Med 2007 
…While the heart 
plucks mandolin strings, 
There, inside 
you filter and apportion 
you separate and divide 
you multiply and lubricate 
you raise and gather  
the threads and grams of life…. 
And after cleaning up, you are warmly last 
to say good bye… 
Ode to the liver 
Pablo Neruda (1904-73) 

